Keith Wilner

7PUBLICATIONS
49CO-AUTHORS
Molecular targetsPredictive and prognostic markersToxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 28, 2026
Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study.

|Jul 02, 2026
Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non-Small Cell Lung Cancers from the PHAROS Study.

|Apr 01, 2026
Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation.

Jeremy A Bartlett, Natalie Culver, Matt Santangelo

|Oct 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.

Melissa L Johnson, Egbert F Smit, Enriqueta Felip

|Dec 17, 2021
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design.

Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip

|Sep 22, 2020
Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.

Kazuhiko Nakagawa, Koichi Matsumura, Tayler Scory

Pageof 2

Frequent Collaborators

3 joint publications

Anne Tsao

3 joint publications

Gregory J Riely

2 joint publications

Kelly A Larkin-Kaiser

2 joint publications

Tayler Scory